Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2024-203673

Published: 2024

Journal Articles

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Blood (2024) 144 (Supplement 1): 4618.

https://doi.org/10.1182/blood-2024-200848

Published: 2024

Journal Articles

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Blood (2024) 144 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2024-200903

Published: 2024

Journal Articles

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Blood (2023) 142 (Supplement 1): 1903.

https://doi.org/10.1182/blood-2023-179767

Published: 2023

Journal Articles

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

Armin Riecke, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Sandra Robrecht, Adam Giza, Lothar Müller, Ursula Vehling-Kaiser, Michael J. Eckart, Werner Freier, Björn Schöttker, Tobias Gaska, Marcel Reiser, Anna-Maria Fink, Barbara F. Eichhorst, Kirsten Fischer, Michael Hallek, Petra Langerbeins, Stephan Stilgenbauer

Blood (2023) 142 (Supplement 1): 199.

https://doi.org/10.1182/blood-2023-180558

Published: 2023

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 3047.

https://doi.org/10.1182/blood-2019-131025

Published: 2019

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

Journal Articles

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

Petra Langerbeins, MD, Jasmin Bahlo, Christina Rhein, Paula Cramer, MD, Anna-Maria Fink, MD, Natali Pflug, MD, Julia von Tresckow, MD, Stephan Stilgenbauer, MD, Karl-Anton Kreuzer, Michael J. Eckart, MD, Ursula Vehling-Kaiser, MD, Rudolf Schlag, MD, Christina Balser, MD, Lothar Müller, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Michael Hallek, MD

Blood (2015) 126 (23): 2934.

https://doi.org/10.1182/blood.V126.23.2934.2934

Published: 2015

Journal Articles

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

Blood (2015) 126 (1): 42–49.

https://doi.org/10.1182/blood-2015-01-617993

Published: 2015

Includes: Supplemental data

Journal Articles

CLL-cells induce IDO hi CD14 + HLA-DR lo myeloid-derived suppressor cells that inhibit T-cell responses and promote T Regs

Regina Jitschin, Martina Braun, Maike Büttner, Katja Dettmer-Wilde, Juliane Bricks, Jana Berger, Michael J. Eckart, Stefan W. Krause, Peter J. Oefner, Katarina Le Blanc, Andreas Mackensen, Dimitrios Mougiakakos

Blood (2014) 124 (5): 750–760.

https://doi.org/10.1182/blood-2013-12-546416

Published: 2014

Includes: Supplemental data

Journal Articles

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Blood (2014) 124 (1): 49–62.

https://doi.org/10.1182/blood-2014-02-556399

Published: 2014

Includes: Supplemental data

Journal Articles

Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia

Regina Jitschin, Andreas D. Hofmann, Heiko Bruns, Andreas Gießl, Juliane Bricks, Jana Berger, Domenica Saul, Michael J. Eckart, Andreas Mackensen, Dimitrios Mougiakakos

Blood (2014) 123 (17): 2663–2672.

https://doi.org/10.1182/blood-2013-10-532200

Published: 2014

Includes: Supplemental data

Journal Articles

The Impact Of Oxidative Stress On The Immune Compartment Of Chronic Lymphocytic Leukemia Patients

Regina Jitschin, Juliane Bricks, Jana Berger, Michael J Eckart, MD, Andreas Mackensen, Dimitrios Mougiakakos

Blood (2013) 122 (21): 4160.

https://doi.org/10.1182/blood.V122.21.4160.4160

Published: 2013

Journal Articles

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

Manuela A. Bergmann, MD, Raymonde Busch, PhD, Barbara Eichhorst, MD, Andreas Buehler, MD, Norbert Fischer, MD, Michael J Eckart, MD, Ursula Vehling-Kaiser, MD, Ulrich Jäger, MD, Georg Hopfinger, MD, Clemens Wendtner, MD, Kirsten Fischer, MD, Bertold Emmerich, MD, Hartmut Döhner, MD, Michael Hallek, M.D. Ph.D., Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 4127.

https://doi.org/10.1182/blood.V122.21.4127.4127

Published: 2013

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D Schweighofer, MD, Raymonde Busch, Jasmin Renschler, Michael Kiehl, MD, Leopold Balleisen, MD, Michael J Eckart, MD, Anna- Maria Fink, MD, Julia Kilp, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F Eichhorst, MD, Michael Hallek, MD, Clemens- Martin Wendtner, MD, The German CLL Study Group

Blood (2008) 112 (11): 330.

https://doi.org/10.1182/blood.V112.11.330.330

Published: 2008

Journal Articles

Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).

Manuela A. Bergmann, MD, Barbara F. Eichhorst, MD, Raymonde Busch, Dagmar Adorf, MD, Stephan Stilgenbauer, MD, Michael J. Eckart, MD, Clemens-Martin Wendtner, MD, Michael Hallek, MD, GCLLSG

Blood (2007) 110 (11): 625.

https://doi.org/10.1182/blood.V110.11.625.625

Published: 2007

NARROW

Informative Censoring in Randomized First-Line Trials of Chronic Lymphocytic Leukemia

Efficacy and Safety of Acalabrutinib Treatment in Very Old (≥80y) and/or Frail Patients with Chronic Lymphocytic Leukemia (CLL) - Primary Endpoint Analysis of the Phase II CLL-Frail Trial

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

IGLV3-21 R110 Is a Prognostic Marker for Early Stage CLL Patients Under Ibrutinib Treatment or Watch & Wait: Results from the Double-Blind, Randomized, Placebo-Controlled GCLLSG CLL12 Trial

Genetic markers and ibrutinib vs placebo treatment in early stage chronic lymphocytic leukemia -results from the GCLLSG CLL12 trial

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV

CLL-cells induce IDO hi CD14 + HLA-DR lo myeloid-derived suppressor cells that inhibit T-cell responses and promote T Regs

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia

The Impact Of Oxidative Stress On The Immune Compartment Of Chronic Lymphocytic Leukemia Patients

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only